drugset / Trial / NCT00154063
Efficacy and Safety Study of E2007 in Migraine Prophylaxis
RandomizedParallel-groupDouble-blindTreatment
Summary
This was a 22-week, prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study that included a 4-week Baseline Phase at the beginning and a 4-week single-blind placebo Safety Phase at the end of the study.
Timeline
- Start
- 2005-01
- Primary completion
- 2006-06
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perampanel | Small molecule | 2 mg | — |
Indications
No indication recorded.